Navigation Links
Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Date:10/5/2007

- Presentation to highlight milestones including phase III development of

'GI-friendly' NSAIDs for mild to moderate pain -

PALO ALTO, Calif., Oct. 5 /PRNewswire/ --

What: Horizon Therapeutics, Inc. is pleased to announce that

George Tidmarsh, M.D., Ph.D., chief executive officer, will

showcase Horizon's corporate and clinical milestones,

including its recent completion of Series C financing, and

provide an update on the development of the Company's

product pipeline during an Open House Podium Presentation

at BioPartnering Europe (BPE). Immediately following the

presentation Dr. Tidmarsh will be available to field

questions and provide more detailed information on Horizon

Therapeutics.

BPE was first held in London in 1993 as a partnership

between the U.S. Commercial Service and Technology Vision

Group LLC to bring about closer ties between American and

European biotechnology companies. From the beginning, BPE

has attracted the support of leading pharmaceutical,

biotechnology, financial and service companies that have

all contributed to making BPE one of the leading

independent partnering events in the world. BPE has a high

rate of sponsor retention, which indicates its prominent

position on the annual conference calendar for many

industry leaders.

When: Monday, October 8, 2007

9:30 a.m. - 12:45 p.m. Open House Podium Presentation

(10:45-10:55 a.m. Horizon presentation)

Where: London, England

QEII Conference Centre

Abbey Room West - Stream 1

Spokespeople: George Tidmarsh, M.D., Ph.D., co-founder and CEO of Horizon

Therapeutics

Barry Golombik, co-founder of Horizon Therapeutics

Contact: Julie Normart

WeissComm Partners

415.946.1087

jnormart@weisscommpartners.com

About Horizon Therapeutics:

Horizon Therapeutics, Inc. is a late stage biopharmaceutical company focused on the rapid development and commercialization of therapeutic treatments for mild-to-moderate pain management. The Company is building a novel portfolio of therapies through innovative combinations of approved pharmaceutical products that seek to improve safety, efficacy, and patient compliance. Its lead product candidate, HZT-501, entered Phase 3 trials in 2007. In addition to HZT-501, Horizon has a pipeline of follow-on pain combination products in earlier stages of development. For more information visit http://www.horizontherapeutics.com.


'/>"/>
SOURCE Horizon Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New hope on the Horizon for People Wishing to Quit Smoking
2. A new horizon
3. Conjoined Indian Twins See Hope On The Horizon
4. Stem cell cure for peripheral vascular disease: New hope on the horizon
5. Oral Flu Vaccine On The Horizon In Russia
6. Rescheduled: Aerial Mosquito Treatment for Philadelphia
7. First Keyhole Heart Valve Surgery Scheduled in Britain
8. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
9. Researchers Present Ways To Reduce The Risk Of Dementia
10. Researchers Present Data Regarding The Efficiency Of Herbs
11. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As President ... are preparing for how his administration could impact the employee benefits industry. James ... changes are most likely to make it through Congress. His discussion will focus ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... on contracted partners to help with process innovation in drug formulation and manufacturing. ... experience along with state-of-the-art analytical equipment in support of their development and manufacturing ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading provider of ... management module. Using this new feature, sleep physicians can now predict the likelihood ... positive airway pressure (CPAP), oral, or other forms of sleep apnea therapy. The ...
(Date:4/24/2017)... ... ... Emmanuel College is introducing enhancements to its RN-to-BSN Degree Program ... of 2017, Emmanuel’s program will allow registered nurses (RN)s to earn a Bachelor of ... little as $14,528. These changes will enable nurses to complete their degree in a ...
(Date:4/24/2017)... , ... April 24, 2017 , ... As part of ... today to honor the victims of the Holocaust and Nazi persecution, Center for ... Hadamar and Auschwitz on its CMATH Champions trip to Germany and Poland next week. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, ... ... at US$ 7,167.6 Mn in 2015, and is expected to ... of 5.6% from 2016 to 2024. The ...
(Date:4/19/2017)... April 19, 2017 Cardiology devices segment is anticipated ... The Cardiology Devices segment is likely to create ... Mn in 2018 over 2017. By the end of 2027, ... close to US$ 700 Mn, expanding at a CAGR of ... the Asia Pacific reprocessed medical devices ...
Breaking Medicine Technology: